<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852017000500346</article-id>
<article-id pub-id-type="doi">10.24245/revmexurol.v77i5.1115</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tumores testiculares: 10 años de experiencia en un hospital de tercer nivel]]></article-title>
<article-title xml:lang="en"><![CDATA[Testicular tumors: Ten years of experience at a tertiary care hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Germán-Garrido]]></surname>
<given-names><![CDATA[CO.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos-Salcedo]]></surname>
<given-names><![CDATA[JG.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bravo-Castro,]]></surname>
<given-names><![CDATA[EI.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Diaz-Gomez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Silvestre]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza-Álvarez]]></surname>
<given-names><![CDATA[LA.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>77</volume>
<numero>5</numero>
<fpage>346</fpage>
<lpage>352</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852017000500346&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852017000500346&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852017000500346&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  el cáncer de testículo es la neoplasia sólida más común en varones entre 15 y 35 años de edad y representa el 1% de todos los cánceres en el hombre, con un riesgo de padecerlo del 0.2%.  OBJETIVO:  reportar la epidemilogía y evolución oncológica de pacientes con tumores testiculares.  MATERIALES Y MÉTODOS: estudio retrospectivo, ambispectivo, efectuado en pacientes con tumores testiculares, atendidos en el Hospital Central de Militar, de enero de 2006 a octubre de 2016. Variables de estudio: factores de riesgo, marcadores tumorales, estadio, clasificación internacional de grupos de riesgo y modalidad de tratamiento. Los desenlaces evaluados fueron: supervivencia libre de recurrencia y supervivencia global.  RESULTADOS:  se seleccionaron 115 pacientes, la estirpe histológica más común fue seminoma (53.4%); en los casos con tumores no seminomatosos se encontró carcinoma embrionario. El 10.4% de los pacientes tenía antecedente de criptorquidia; 85% se clasificó de riesgo bajo, 9% de riesgo intermedio y 6% de riesgo alto. El tratamiento inicial consistió en orquiectomía y vigilancia activa en 15 casos, orquiectomía y radioterapia en 19, orquiectomía y quimioterapia en 65, y quimioterapia y orquiectomía en 2 casos. La supervivencia libre de enfermedad a 3 años fue de 98% en el grupo de bajo riesgo, 87% en el de riesgo intermedio y 66.7% en el de alto riesgo. La supervivencia global a 3 años fue de 99, 100 y 66.7%, respectivamente (p &lt; 0.0001).  CONCLUSIONES:  el tratamiento de pacientes con tumores testiculares debe ser multidisciplinario y basado en la clasificación internacional de grupos de riesgo riesgo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  Testicular cancer is the most common solid tumor in men between 15 and 35 years of age. It represents 1% of all cancers in males, with a 0.2% lifetime risk for developing the disease.  AIMS:  To examine and describe the epidemiology and oncologic progression of testicular tumor in patients treated at our hospital.  MATERIALS AND METHODS:  An ambispective study was conducted on patients seen at the Hospital Militar Central within the time frame of January 2006 and October 2016. We conducted a retrospective analysis of the risk factors, tumor markers, tumor stage, international risk group classification, and treatment modality. The outcomes evaluated were recurrence-free survival and overall survival.  RESULTS:  The study included 115 patients. The most common histologic strain was seminoma (53.4%) and in the nonseminomatous tumors it was embryonal carcinoma. A total of 10.4% of the cases had a history of cryptorchidism. Eighty-five percent of the cases were low risk, 9% were intermediate risk, and 6% were high-risk. The initial treatment modality was orchiectomy plus active surveillance in 15 cases, orchiectomy plus radiotherapy in 19 cases, orchiectomy plus chemotherapy in 65 cases, and chemotherapy followed by orchiectomy in 2 cases. Three-year disease-free survival was 98% in the low-risk group, 87% in the intermediate-risk group, and 66.7% in the high-risk group. Overall 3-year survival was 99% for the lowrisk group, 100% for the intermediate-risk group, and 66.7% for the high-risk group (p&lt;0.0001).  CONCLUSION:  Testicular tumor management should be multidisciplinary and based on the international risk group classification.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[tumores testiculares]]></kwd>
<kwd lng="es"><![CDATA[criptorquidia]]></kwd>
<kwd lng="es"><![CDATA[neoplasia de células germinales]]></kwd>
<kwd lng="en"><![CDATA[Testicular tumors]]></kwd>
<kwd lng="en"><![CDATA[Cryptorchidism]]></kwd>
<kwd lng="en"><![CDATA[Germ cell neoplasia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics 2016]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2016</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Surveillance, Epidemiology, and End Results (SEER) Program</collab>
<source><![CDATA[Cancer statistics 2014]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeSantis]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Mariotto]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer treatment and survivorship statistics, 2014]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2014</year>
<volume>64</volume>
<page-range>252-71</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and diagnosis of testis cancer]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2015</year>
<volume>42</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>269-75</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moch]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Humphrey]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Ulbright]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<source><![CDATA[Tumours of the Urinary System and Male Genital Organs]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Lyon ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization Classification of Tumours]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Testicular germ-cell cáncer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>337</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>242</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Ríos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Solares-Sánchez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cervera]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Panorama epidemiológico del cáncer genitourinario en la zona centro de México]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2011</year>
<volume>71</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>36-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedano-Basilio]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Mayorga-Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología de los tumores genitourinarios en una década]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2016</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edge]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Byrd]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Compton]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<source><![CDATA[AJCC Cancer Staging Manual]]></source>
<year>2010</year>
<edition>7</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>International Germ Cell Cancer Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1997</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>594-603</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Germà-Lluch]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[García-del Muro]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Maroto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumors of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2002</year>
<volume>42</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>553-62</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio descriptivo de los tumores testiculares germinales: 13 años de experiencia en el área de Badajoz]]></article-title>
<source><![CDATA[Arch Esp Urol]]></source>
<year>2007</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>531-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
